1-4 of 4
Chean Eng Ooi
Close
Sort by
Journal Articles

Efficacy and Safety of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302

Francine M. Foss, Youn H. Kim, H. Miles Miles Prince, Timothy M. Kuzel, Costas K. Yannakou, Chean Eng Ooi, Dongyuan Xing, Nicholas Sauter, Preeti Singh, Myron Czuczman, Madeleine Duvic
Journal: Blood
Blood (2022) 140 (Supplement 1): 1491–1492.
https://doi.org/10.1182/blood-2022-166916
Published: 2022
Journal Articles

Safety and Tolerability of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302

H. Miles Miles Prince, Larisa J Geskin, Oleg E Akilov, Timothy M. Kuzel, Christiane Querfeld, Chean Eng Ooi, Dongyuan Xing, Nicholas Sauter, Preeti Singh, Myron Czuczman, Francine M. Foss
Journal: Blood
Blood (2022) 140 (Supplement 1): 6577–6578.
https://doi.org/10.1182/blood-2022-167564
Published: 2022
Journal Articles

A Dose Finding Lead-in Study of E7777 (Diphtheria toxin fragment-Interleukin-2 Fusion Protein) in Persistent or Recurrent Cutaneous T-Cell Lymphoma (CTCL)

Madeleine Duvic, MD, Timothy M Kuzel, MD, Nam H. Dang, MD PhD, Miles Prince, MD FRACP, FRCPA, Tatyana Feldman, MD, Francine M. Foss, MD, Matthew Guo, PhD, Lone Harild Ottesen, MD PhD, Chean Eng Ooi, PhD, Youn H Kim, MD
Journal: Blood
Blood (2014) 124 (21): 3097.
https://doi.org/10.1182/blood.V124.21.3097.3097
Published: 2014
Journal Articles

A Phase II Study of PXD101 in Advanced Multiple Myeloma.

Daniel Sullivan, MD, Seema Singhal, MD, Michael Schuster, MD, James Berenson, MD, Peter Gimsing, MD, Finn Wislöff, MD, Anders Waage, MD, Melissa Alsina, MD, Robert Gerwien, PhD, Anne Clarke, RN, MPH, Karen Moller, Chean Eng Ooi, PhD
Journal: Blood
Blood (2006) 108 (11): 3583.
https://doi.org/10.1182/blood.V108.11.3583.3583
Published: 2006